TABLE 1.
Baseline demographics according to exacerbation history in the year prior to screening
| Subgroup | |||
| Single moderate | Frequent moderate | Severe | |
| Subjects | 3056 (30) | 4628 (45) | 2671 (26) |
| Age years | 65.2±7.95 | 65.3±8.46 | 65.4±8.29 |
| Male | 2069 (68) | 2922 (63) | 1879 (70) |
| White | 2408 (79) | 3604 (78) | 1971 (74) |
| Former smoker | 1964 (64) | 3014 (65) | 1790 (67) |
| BMI kg·m−2 | 26.10±6.043 | 27.03±5.833 | 26.52±6.532 |
| Lung function post-bronchodilator | |||
| At screening FEV1 L | 1.046±0.3193 | 1.437±0.5036 | 1.247±0.5037 |
| FEV1 % predicted | 37.0±8.85 | 51.9±14.77 | 44.4±15.25 |
| FEV1/FVC ratio | 0.421±0.1028 | 0.510±0.1161 | 0.458±0.1201 |
| Baseline# concomitant COPD medication at screening alone or in combination | |||
| LAMA | 243 (8) | 375 (8) | 213 (8) |
| LABA | 84 (3) | 166 (4) | 41 (2) |
| LAMA+LABA | 327 (11) | 392 (8) | 215 (8) |
| ICS+LABA | 906 (30) | 1694 (37) | 741 (28) |
| ICS+LAMA+LABA | 1258 (41) | 1651 (36) | 1274 (48) |
| Baseline blood eosinophil counts | |||
| 203±186 | 230±256 | 232±242 | |
| Patients with count % | |||
| <100 | 26 | 25 | 24 |
| 100–300 | 55 | 53 | 52 |
| >300 | 19 | 23 | 23 |
Date are presented as n (%) or mean±sd, unless otherwise stated. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist. #: between day of screening −3 days and date of screening (inclusive).